New Drug Candidate Shows Promise in Reversing Stroke Damage
A novel drug candidate, KDS12025, is demonstrating promising results in preclinical trials, offering a potential new approach to treating ischemic stroke. Developed by a joint research team from the Institute for Basic Science (IBS) and Eulji University, the drug has shown the ability to restore motor function in animal models, even when administered days after stroke onset. This breakthrough challenges conventional thinking about the “golden hour” for stroke treatment and could significantly expand the therapeutic window for intervention.
Understanding Ischemic Stroke and the Role of Astrocytes
Ischemic stroke, caused by a blockage in a cerebral blood vessel, is a leading cause of disability and death worldwide. In South Korea alone, approximately 100,000 people experience a stroke each year, representing about 10% of all deaths, or one stroke patient every five minutes. Dong-A Science Current treatment primarily focuses on administering thrombolytic agents to quickly restore blood flow, but effective therapies to mitigate long-term damage remain limited.
Recent research has focused on the role of astrocytes, star-shaped cells in the brain, in the aftermath of a stroke. Traditionally, astrocytes were believed to form a protective barrier around damaged tissue, limiting the spread of injury. Though, a team led by Director C. Justin Lee of the IBS Center for Cognition and Sociality has discovered that this glial barrier can actually contribute to neuronal death. AJU Press
The Hydrogen Peroxide-Collagen Pathway and KDS12025
The research team identified a key mechanism driving this detrimental process: a surge in hydrogen peroxide during a stroke activates astrocytes, leading to the production of type I collagen. This collagen buildup forms the glial barrier, but also triggers the death of nerve cells. AJU Press
KDS12025 is designed to target this pathway by both removing hydrogen peroxide and inhibiting collagen production. In mouse models, the drug significantly reduced glial barrier formation and neuronal death, leading to a restoration of impaired motor function within a week. AJU Press Importantly, the drug remained effective even when administered two days after stroke onset, suggesting a potential to extend the critical treatment window.
Promising Results in Primate Models
The efficacy of KDS12025 was further demonstrated in primate models, which more closely mimic human physiology. Three days after administration, lesion size was reduced, and within a week, paralyzed hand function was restored. In a fruit-grasping test, primates treated with KDS12025 successfully completed all 10 attempts, while the untreated control group struggled due to motor impairment. Chosun.com
Looking Ahead: Potential for Clinical Application
These findings suggest that KDS12025 holds significant promise for clinical application in stroke treatment. The ability to extend the therapeutic window beyond the traditional “golden hour” could dramatically improve outcomes for patients who are unable to receive immediate medical attention. Chosun.com Further research and clinical trials will be necessary to confirm the drug’s safety and efficacy in humans, but the initial results represent a major step forward in the fight against stroke.